Search

Displaying results 3071 - 3080 of 9714 in total
  1. Drug

    Diclofenac etalhyaluronate

    go.drugbank.com/drugs/DB20937
    Experimental

    Diclofenac etalhyaluronate has a monoisotopic molecular weight of 1475.39 Da. … Diclofenac etalhyaluronate is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Diclofenac etalhyaluronate is a anti-inflammatory agent, ibufenac derivative.

  2. Drug

    Firuglipel

    go.drugbank.com/drugs/DB19506
    Investigational

    Firuglipel has a monoisotopic molecular weight of 467.19 Da. … Firuglipel is a small molecule drug. Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin).

  3. Drug

    Xemilofiban

    go.drugbank.com/drugs/DB21058
    Experimental

    Xemilofiban has a monoisotopic molecular weight of 358.16 Da. … Xemilofiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Xemilofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  4. Drug

    Amdizalisib

    go.drugbank.com/drugs/DB21514
    Investigational

    Amdizalisib has a monoisotopic molecular weight of 390.11 Da. … Amdizalisib is a small molecule drug.

  5. Drug

    Inaxaplin

    go.drugbank.com/drugs/DB21521
    Investigational

    Inaxaplin has a monoisotopic molecular weight of 417.13 Da. … Inaxaplin is a small molecule drug.

  6. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing … [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function

  7. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With [Peginterferon Alfa-2a

  8. Drug

    Ribuvaptan

    go.drugbank.com/drugs/DB20059
    Experimental

    Ribuvaptan has a monoisotopic molecular weight of 595.11 Da. … Ribuvaptan is a small molecule drug. The usage of the INN stem '-vaptan' in the name indicates that Ribuvaptan is a vasopressin receptor antagonist.

  9. Drug

    Fasobegron

    go.drugbank.com/drugs/DB20200
    Experimental

    Fasobegron has a monoisotopic molecular weight of 425.14 Da. … Fasobegron is a small molecule drug. The usage of the INN stem '-begron' in the name indicates that Fasobegron is a β3​ adrenoreceptor agonists.

  10. Drug

    Ruclosporin

    go.drugbank.com/drugs/DB21199
    Experimental

    Ruclosporin has a monoisotopic molecular weight of 1330.92 Da. … Ruclosporin is a small molecule drug. The usage of the INN stem '-(clo)sporin' in the name indicates that Ruclosporin is a cyclosporine derivative.